Navigation Links
CorMedix to Report Third Quarter Financial Results on November 19, 2013

BRIDGEWATER, N.J., Nov. 15, 2013 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the Company will report financial results for the third quarter ended September 30, 2013 after the close of trading on Tuesday, November 19, 2013.

CorMedix has filed form 12b-25 with the U.S. Securities and Exchange Commission (the "SEC"), and as a result, the deadline for the Company to file its quarterly report on Form 10-Q with the SEC has been extended to November 19, 2013.

CorMedix management will hold a conference call on Wednesday, November 20, 2013, at 9a.m. EST to discuss the results and provide an update on recent business developments.  To access the call, please dial 1-866-866-1333 in the United States, and 1-404-260-1421 internationally.  A live webcast of the conference call will also be available on the investor relations page of the Company's website at

For those unable to participate, a telephonic replay of the call will be available until December 4, 2013.  The replay dial-in numbers are 1-866-430-1300 for domestic callers and 1-404-260-1414 for international callers.  Please use event PIN 4804300 and confirmation number 201311142204363 to access the replay. Additionally, an archived webcast of the event will be available on the CorMedix website for 90 days.

About CorMedix

CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's most advanced product candidate is Neutrolin®, catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Please see the company's website at for additional information.

(Logo: )

SOURCE CorMedix Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
2. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
3. CorMedix Reports Second Quarter 2013 Results
4. CorMedix Granted Extension of NYSE MKT Listing
5. ULURU Inc. Reports Third Quarter 2013 Financial Results
6. China Pharma Holdings, Inc. Reports Third Quarter 2013 Financial Results
7. TPI Reports First Quarter Fiscal Year 2014 Financial Results
8. Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
9. Vermillion Reports Third Quarter 2013 Results
10. Global Radiopharmaceutical Market 2012-2016 Reports
11. SPO Global Reports Results for Third Quarter 2013
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 As enforcement of ... Chain Security Act (DSCSA) approaches, InfiniTrak ... independent pharmacies comply with looming FDA regulations. ... is entering endorsement agreements with State Pharmacy Associations, ... administration organization (PSAO) to exclusively provide the InfiniTrak ...
(Date:12/1/2015)... ) ... "Spinal Muscular Atrophy Market - Pipeline Assessment, ... 2023" report to their offering. ... addition of the "Spinal Muscular Atrophy ... and Forecast 2015 - 2023" report ...
(Date:12/1/2015)... AMSTERDAM , Dec. 1, 2015 /PRNewswire/ -- ... announced SkyFlow , an X-ray imaging software that ... clinicians decide not to use a grid, at the ... (RSNA) 1 . SkyFlow is Philips, first digital ... for grid-less radiography, which improves clinician,s workflow and supports ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... World Patent ... Multi Jar, a container patent that allows for easier packing and organizing of items ... is worth $90 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:12/1/2015)... ... December 02, 2015 , ... ... events and association with initiation of treatment for osteoporosis ”. , As corresponding ... pharmacological treatment in patients diagnosed with osteoporosis. Based on a large US managed ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated ... acquisition by Jordan Industries International, LLC (“JII”). , With support from JII, Integrated ... maintenance services to hospitals, surgery centers, clinics, research labs and medical facilities across ...
(Date:12/1/2015)... ... 2015 , ... According to an article published on November 16th ... the U.S. Department of Health and Human Services, claiming that any states which do ... the clause in the law prohibiting the denial of coverage for pre-existing conditions. The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
Breaking Medicine News(10 mins):